Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company decreased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 540,913 shares of the company’s stock after selling 2,488 shares during the period. The Manufacturers Life Insurance Company owned approximately 1.09% of Prestige Consumer Healthcare worth $39,000,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Ariel Investments LLC boosted its stake in shares of Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after buying an additional 274,212 shares during the period. Victory Capital Management Inc. lifted its position in Prestige Consumer Healthcare by 9.0% in the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after purchasing an additional 171,357 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Prestige Consumer Healthcare by 19.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after purchasing an additional 255,045 shares during the period. Congress Asset Management Co. lifted its position in Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after purchasing an additional 62,411 shares during the period. Finally, Boston Trust Walden Corp acquired a new stake in Prestige Consumer Healthcare in the third quarter valued at about $41,785,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Up 1.2 %

Shares of Prestige Consumer Healthcare stock opened at $84.17 on Friday. Prestige Consumer Healthcare Inc. has a 12-month low of $56.61 and a 12-month high of $86.36. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The stock has a market cap of $4.16 billion, a PE ratio of 20.48, a price-to-earnings-growth ratio of 2.38 and a beta of 0.47. The company has a 50-day moving average of $75.17 and a two-hundred day moving average of $71.06.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period last year, the company posted $1.07 earnings per share. The firm’s quarterly revenue was down .9% compared to the same quarter last year. On average, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William P’pool sold 8,987 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. DA Davidson restated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.